Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 253 clinical trials
A Phase I Dose Escalation Study for Patients With Recurrent Malignant Gliomas

This is a clinical trial (a type of research study). Clinical trials include only patients who choose to take part. You are being asked to take part in this study because you have a brain tumor that continued to grow despite prior therapy. Currently, there is no known effective treatment …

  • 07 Nov, 2020
  • 1 location
Genomic Landscape of Intramedullary Astrocytoma

intramedullary astrocytoma is a rare and devastating spinal cord glioma. while the management of intracranial astrocytoma includes gross total resection, radiotherapy and chemotherapy, spinal

  • 23 Jan, 2021
  • 1 location
Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors

classification, which includes genomic characterization, comprises more than 100 CNS tumor entities and subclasses. In children, glial lineage tumors (gliomas) are the most frequent and comprise astrocytomas

  • 04 Mar, 2021
  • 1 location
3D Prediction of Patient-Specific Response (3D-PREDICT)

This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.

cytotoxic chemotherapy
cancer of the ovary
cancer chemotherapy
  • 26 Apr, 2022
  • 9 locations
Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients

I (pilocytic astrocytoma) and grade II (diffuse astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and pleomorphic xanthoastrocytoma) are termed low-grade gliomas (LGGs), whereas grade III

  • 27 Jan, 2021
  • 1 location
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of …

proton therapy
karnofsky performance status
  • 04 May, 2022
  • 3 locations
The Registry of Oncology Outcomes Associated With Testing and Treatment

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and …

lab tests
diagnostic procedures
primary cancer
  • 22 Oct, 2021
  • 1 location
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes (RIGEL)

Rationale: Standard postoperative treatment of isocitrate dehydrogenase 1/2 mutated grade 2 and 3 glioma (IDHmG) consists of radiotherapy and chemotherapy. The improving prognosis of these patients leads towards more emphasis on the long-term effects of treatment. Specifically radiotherapy has been implicated in the development of delayed neurocognitive deterioration. The impact …

  • 01 Mar, 2022
  • 2 locations
Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study …

brain tumor
glioblastoma multiforme
treatment regimen
  • 15 Sep, 2022
  • 1 location
Social Determinants of Health in Glioblastoma Population

The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and community-level factors. This will be conducted in two parts.

  • 29 Jul, 2022
  • 1 location